SAB Biotherapeutics Inc — Quarterly Dividends (NASDAQ:SABS) | MetaTrader

Open full chart

Notizie

Azioni SAB Biotherapeutics: UBS avvia copertura con rating Buy per potenziale farmaco contro il diabete

SAB Biotherapeutics stock initiated with Buy rating at UBS on diabetes drug potential

Guggenheim inizia la copertura del titolo SAB Biotherapeutics con rating Buy

Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential

SAB Biotherapeutics riduce le dimensioni del consiglio dopo le dimissioni di due direttori

SAB Biotherapeutics reduces board size following resignations of two directors

Gli azionisti di SAB Biotherapeutics approvano la modifica al piano azionario e la proposta di conversione della Serie B

SAB Biotherapeutics shareholders approve equity plan amendment and Series B conversion proposal

SAB Biotherapeutics mantiene rating Buy di H.C. Wainwright dopo dati positivi sul trattamento del diabete

SAB Biotherapeutics stock maintains Buy rating at H.C. Wainwright on positive diabetes treatment data

Chardan Capital lowers SAB Biotherapeutics stock price target to $12 from $20

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release